ArticleBrain : a journal of neurology2022
Models of psychedelic drug action: modulation of cortical-subcortical circuits.
Article in Brain : a journal of neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
91 citing papers in PubMed, 4 syntheses or guidelines pooled it, 184 citations in OpenAlex.
- Acute effects of psilocybin on attention and executive functioning in healthy volunteers: a systematic review and multilevel meta-analysis.Psychopharmacology · 2025Pooled it
- Catalyst for change: Psilocybin's antidepressant mechanisms-A systematic review.Journal of psychopharmacology (Oxford, England) · 2025Pooled it
- What fMRI studies say about the nature of the psychedelic effect: a scoping review.Frontiers in neuroscience · 2025Pooled it
- Default Mode Network Modulation by Psychedelics: A Systematic Review.The international journal of neuropsychopharmacology · 2023Pooled it
- Psilocybin produces amplified acute responses and sex-specific long-term increases in sensorimotor gating in the mGlu5 knockout mouse model of schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Article
- Resetting the hippocampal buffer: a neurocognitive account of psychedelic therapy for anxiety-related psychopathology.Psychopharmacology · 2026Review
- Intact neurophysiological markers of death denial in long-term ayahuasca users.Psychopharmacology · 2026Article
- Psychedelics do not always enhance cognitive flexibility: The potential role of time-varying effects on reward learning processes.Neuroscience and biobehavioral reviews · 2026Review
- A suite of engineered mice for interrogating psychedelic drug actions.Nature neuroscience · 2026Article
- Serotonergic psychedelics induce distinct patterns of metabolic activity and covariance within biologically informed rat brain networks.Nature communications · 2026Article
- New functional insights from the monkey claustrum.National science review · 2026Review
- Developmental and cell type-specific contributions of thalamic serotonin 2A receptors to absence seizures.Epilepsia · 2026Article
- Modeled Long-Term Effects of Psilocybin on Dynamic Activity and Effective Connectivity of Fronto-Striatal-Thalamic Circuits.Human brain mapping · 2026Article
- Multi-metric evaluations of acute psychedelic effects on fMRI brain entropy.Nature communications · 2026Article
- An international mega-analysis of psychedelic drug effects on brain circuit function.Nature medicine · 2026Article
- Predictors of the Effectiveness of Psychedelics in Treating Depression-A Scoping Review.International journal of molecular sciences · 2026Article
- Opioid Receptors in Psychedelia: Indirect Serotonergic Modulation of Direct KOR Activation by Salvinorin A.Biomedicines · 2026Review
- Cognitive control as a transdiagnostic mechanism of action in psychedelic effects.Cognitive, affective & behavioral neuroscience · 2026Review
- The effect of psilocin on neurotransmitters release in the claustrum and on rat behavior.Pharmacological reports : PR · 2026Article
31 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Classic psychedelic drugs such as psilocybin and lysergic acid diethylamide (LSD) have recaptured the imagination of both science and popular culture, and may have efficacy in treating a wide range of psychiatric disorders. Human and animal studies of psychedelic drug action in the brain have demonstrated the involvement of the serotonin 2A (5-HT2A) receptor and the cerebral cortex in acute psychedelic drug action, but different models have evolved to try to explain the impact of 5-HT2A activation on neural systems. Two prominent models of psychedelic drug action (the cortico-striatal thalamo-cortical, or CSTC, model and relaxed beliefs under psychedelics, or REBUS, model) have emphasized the role of different subcortical structures as crucial in mediating psychedelic drug effects. We describe these models and discuss gaps in knowledge, inconsistencies in the literature and extensions of both models. We then introduce a third circuit-level model involving the claustrum, a thin strip of grey matter between the insula and the external capsule that densely expresses 5-HT2A receptors (the cortico-claustro-cortical, or CCC, model). In this model, we propose that the claustrum entrains canonical cortical network states, and that psychedelic drugs disrupt 5-HT2A-mediated network coupling between the claustrum and the cortex, leading to attenuation of canonical cortical networks during psychedelic drug effects. Together, these three models may explain many phenomena of the psychedelic experience, and using this framework, future research may help to delineate the functional specificity of each circuit to the action of both serotonergic and non-serotonergic hallucinogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.